Sakar Healthcare's Q2 FY 2025-26 Quarterly Results

Result Summary

• Sakar Healthcare Ltd reported a 10.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 36.2%.
• Its expenses for the quarter were up by 11.9% QoQ and 40.4% YoY.
• The net profit decreased 2.8% QoQ and decreased 5.4% YoY.
• The earnings per share (EPS) of Sakar Healthcare Ltd stood at 2.03 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sakar Healthcare Ltd is a company operating in the pharmaceutical industry. The company is engaged in the manufacturing and marketing of pharmaceutical formulations. While specifics about its main products or recent developments were not provided, companies in this sector typically produce a range of generic and branded medicines. Sakar Healthcare Ltd may be involved in producing tablets, capsules, injectables, and other dosage forms. Recent developments in such companies often revolve around product launches, regulatory approvals, or expansion into new markets. However, detailed information about any recent major developments for Sakar Healthcare Ltd was not provided.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), Sakar Healthcare Ltd reported a total income of ₹58.78 crores. This represents an increase of 10.6% quarter-over-quarter (QoQ) from ₹53.13 crores in the first quarter of fiscal year 2026 (Q1FY26) and a significant year-over-year (YoY) growth of 36.2% from ₹43.15 crores in the second quarter of fiscal year 2025 (Q2FY25). This growth in revenue highlights an upward trend in the company's income generation over both the quarterly and yearly periods examined.

Profitability

The company's profit before tax in Q2FY26 stood at ₹5.36 crores, slightly decreasing by 0.4% from ₹5.38 crores in Q1FY26. Compared to the same quarter in the previous year (Q2FY25), there was a 4.9% increase from ₹5.11 crores. Despite the increase in total income, the profit after tax decreased by 2.8% QoQ to ₹4.54 crores from ₹4.67 crores in Q1FY26 and by 5.4% YoY from ₹4.80 crores in Q2FY25. The tax expense saw a substantial increase of 15.5% QoQ and 164.5% YoY, which may have impacted the net profitability.

Operating Metrics

The earnings per share (EPS) for Q2FY26 was ₹2.03, marking a decline of 3.8% from ₹2.11 in Q1FY26 and a 6.0% decrease from ₹2.16 in Q2FY25. This decline in EPS indicates a reduction in shareholder earnings over the periods examined. Total expenses for Q2FY26 were ₹53.42 crores, reflecting an 11.9% increase QoQ from ₹47.74 crores in Q1FY26 and a 40.4% increase YoY from ₹38.04 crores in Q2FY25. The increase in expenses outpaced the growth in total income, contributing to the observed trends in profitability and EPS.